The concept of oncometabolite was established by the studies that mutations of isocitrate dehydrogenase 1 (IDH1) and IDH2 generate a novel metabolite 2-hydroxyglutarate (2-HG) that exhibits oncogenic activity in acute myeloid leukemia and glioma [32],[33]. Here, IDH1 is linked to central nervous system cancer.